Marvell (MRVL) stock slides with tech as Trump tariff threat jolts Wall Street — what to watch next
21 January 2026
1 min read

Marvell (MRVL) stock slides with tech as Trump tariff threat jolts Wall Street — what to watch next

New York, Jan 20, 2026, 20:46 EST — Market closed.

Marvell Technology, Inc. (MRVL.O) slipped roughly 0.8% to $79.80 on Tuesday, following a session that saw its shares swing between $83.45 and $77.17. Trading volume hit around 18.7 million shares.

Wall Street took its sharpest tumble in three months after President Donald Trump announced new tariffs on several European countries, set to kick in at 10% on Feb. 1 and jump to 25% by June 1—unless the U.S. succeeds in buying Greenland. The S&P 500 dropped 2.06%, the Nasdaq slid 2.39%, and both slipped below their 50-day moving averages, a key level for short-term traders. Meanwhile, the Cboe Volatility Index, Wall Street’s fear gauge, hit its highest mark since late November. Jamie Cox, managing partner at Harris Financial Group, said he isn’t convinced yet that the tariff threat will spark a wider correction, especially with the Personal Consumption Expenditures (PCE) report—the Fed’s favored inflation measure—due later this week. 1

Marvell’s stock is particularly sensitive to changes in risk appetite as Wednesday approaches. When investors turn “risk-off” and flock to safer assets, semiconductors often see sharper moves than the overall market.

Tariff discussions complicate matters further for the chip industry. With supply chains spanning multiple countries and major buyers planning capital expenditures months in advance, even just the threat of tariffs can cloud demand forecasts and delay decisions.

Marvell is doubling down on data-center connectivity. Earlier this month, it announced plans to acquire XConn Technologies, a networking equipment maker, for about $540 million. The deal, split roughly 60% cash and 40% stock, is set to close in early 2026. This move aims to bolster Marvell’s AI data-center hardware lineup and ramp up competition against bigger players like Broadcom and Nvidia. 2

Tuesday’s wide intraday swings highlighted just how fast traders pivot on high-growth stocks when policy news breaks. A small move in rates or even an offhand tariff remark can quickly flip momentum.

That said, the situation works both ways. Should Washington ease up or investors conclude the threats are mostly bluster, chip stocks could rebound just as fast as they dropped.

The downside looks rougher: a drawn-out trade war pushing up costs, shaking confidence, and crimping tech budgets, all while bond yields remain elevated. In that scenario, investors tend to apply lower multiples to firms that rely on steady growth to back their valuations.

Wasif Latif, chief investment officer at Sarmaya Partners, noted that “geopolitical risks … are re-emerging,” as traders factored the tariff threat back into asset prices. European leaders plan to meet for an emergency summit in Brussels on Thursday to weigh their options. 3

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Caterpillar stock drops nearly 3% as tariff jitters rattle industrials — what to watch next
Previous Story

Caterpillar stock drops nearly 3% as tariff jitters rattle industrials — what to watch next

Qualcomm stock extends seven-day skid as tariff fears rattle tech; QCOM earnings up next
Next Story

Qualcomm stock extends seven-day skid as tariff fears rattle tech; QCOM earnings up next

Go toTop